Abivax S.A. ABVX 深 滬
等待開盤 12-17 09:30:00 美东时间
110.98
-6.930
-5.88%
華盛通- 最 高115.61
- 今 開113.00
- 成交量 226.67万股
- 最 低 108.525
- 昨 收 117.91
- 總市值 85.94亿
- 52周最高 138.4899
- 市盈率 靜 --
- 換手率 2.93%
- 52周最低 4.77
- 委 比 60.00%
- 總股本 7743.38万
- 歷史最高 138.4899
- 量 比 0.89
- 振 幅 6.01%
- 歷史最低 4.77
- 每 手 1
- 風險率 43.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
今天 10:46
Citizens Maintains Market Outperform on Abivax, Raises Price Target to $131
Citizens analyst Jason Butler maintains Abivax (NASDAQ:ABVX) with a Market Outperform and raises the price target from $114 to $131.
12-16 19:18
What's Happening With French Biotech Abivax Stock On Wednesday?
Abivax shares rise on renewed takeover speculation tied to Eli Lilly following strong Phase 3 trial results.
12-11 01:42
Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite falling more than 100 points ...
12-10 23:41
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $140
Truist Securities analyst Gregory Renza initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $140.
11-25 01:47
6 Healthcare Stocks With Strong Upward Momentum
Out with the old (tech), in with the new (healthcare). After several volatile w...
11-19 01:59
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Wolfe Research Initiates Coverage On Abivax with Outperform Rating, Announces Price Target of $176
Wolfe Research analyst Steve Fleishman initiates coverage on Abivax (NASDAQ:ABVX) with a Outperform rating and announces Price Target of $176.
11-06 21:22
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
